- Home
- PRCT vs MRUS Comparison
PRCT vs MRUS Comparison
Compare PRCT & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- MRUS
- Stock Information
- Founded
- PRCT 2009
- MRUS 2003
- Country
- PRCT United States
- MRUS Netherlands
- Employees
- PRCT N/A
- MRUS N/A
- Industry
- PRCT Medical Specialities
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- MRUS Health Care
- Exchange
- PRCT Nasdaq
- MRUS Nasdaq
- Market Cap
- PRCT 3.2B
- MRUS 3.3B
- IPO Year
- PRCT 2021
- MRUS 2016
- Fundamental
- Price
- PRCT $58.79
- MRUS $44.35
- Analyst Decision
- PRCT Strong Buy
- MRUS Strong Buy
- Analyst Count
- PRCT 7
- MRUS 13
- Target Price
- PRCT $94.29
- MRUS $86.85
- AVG Volume (30 Days)
- PRCT 904.1K
- MRUS 649.5K
- Earning Date
- PRCT 04-24-2025
- MRUS 05-07-2025
- Dividend Yield
- PRCT N/A
- MRUS N/A
- EPS Growth
- PRCT N/A
- MRUS N/A
- EPS
- PRCT N/A
- MRUS N/A
- Revenue
- PRCT $224,498,000.00
- MRUS $36,133,000.00
- Revenue This Year
- PRCT $46.28
- MRUS $37.72
- Revenue Next Year
- PRCT $32.67
- MRUS $48.47
- P/E Ratio
- PRCT N/A
- MRUS N/A
- Revenue Growth
- PRCT 64.84
- MRUS N/A
- 52 Week Low
- PRCT $45.56
- MRUS $37.77
- 52 Week High
- PRCT $103.81
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- PRCT 43.67
- MRUS 46.95
- Support Level
- PRCT $56.14
- MRUS $44.20
- Resistance Level
- PRCT $64.38
- MRUS $49.80
- Average True Range (ATR)
- PRCT 2.76
- MRUS 2.01
- MACD
- PRCT 0.80
- MRUS -0.47
- Stochastic Oscillator
- PRCT 44.05
- MRUS 15.32
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.